Edition:
India

BioDelivery Sciences International Inc (BDSI.OQ)

BDSI.OQ on NASDAQ Stock Exchange Capital Market

2.05USD
22 Feb 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$2.05
Open
$2.05
Day's High
$2.10
Day's Low
$2.00
Volume
57,568
Avg. Vol
79,817
52-wk High
$3.60
52-wk Low
$1.58

Chart for

About

BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products... (more)

Overall

Beta: 0.86
Market Cap(Mil.): $166.43
Shares Outstanding(Mil.): 55.48
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.60
EPS (TTM): -- -- --
ROI: -- 14.90 10.66
ROE: -- 16.41 14.30

BRIEF-Biodelivery Sciences Announces Belbuca Patent Litigation Settlement Agreement With Teva

* BIODELIVERY SCIENCES ANNOUNCES BELBUCA PATENT LITIGATION SETTLEMENT AGREEMENT WITH TEVA

06 Feb 2018

BRIEF-BioDelivery Sciences Announces Launch And Availability Of Belbuca In Canada

* BIODELIVERY SCIENCES ANNOUNCES LAUNCH AND AVAILABILITY OF BELBUCA® IN CANADA Source text for Eikon: Further company coverage:

30 Jan 2018

BRIEF-BioDelivery Sciences Reacquires Onsolis From Collegium Pharmaceutical

* BIODELIVERY SCIENCES REACQUIRES ONSOLIS® FROM COLLEGIUM PHARMACEUTICAL

15 Dec 2017

BRIEF-BioDelivery Sciences Says ‍Ohio Workers Compensation Approved Change To Formulary

* BIODELIVERY SCIENCES - ‍OHIO BUREAU OF WORKERS COMPENSATION APPROVED CHANGE TO ITS FORMULARY RESULTING IN FAVORABLE POSITIONING FOR BELBUCA, BUNAVAIL

27 Nov 2017

BRIEF-BioDelivery Sciences reports Q3 loss per share $0.21

* BioDelivery Sciences reports third quarter 2017 financial results and provides corporate update

10 Nov 2017

BRIEF-BioDelivery sciences announces patent litigation settlement agreement with Teva

* BioDelivery Sciences announces patent litigation settlement agreement with Teva

12 Oct 2017

BRIEF-BioDelivery Sciences CEO Mark Sirgo to retire

* BioDelivery Sciences president and chief executive officer Mark Sirgo to retire at year-end while continuing as vice chairman

23 Aug 2017

Earnings vs. Estimates